Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases

Expert Reviews in Molecular Medicine

Volumn 2, Issue 1, 2000, Pages 1-17

  Platt, Frances M ^a   Butters, Terry D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

glycosphingolipid; glycosphingolipids; imino sugar; imino sugars; lysosomal storage disease; N butyldeoxygalactonojirimycin; N butyldeoxynojirimycin; Sandhoff disease; substrate deprivation; Tay Sachs disease

Indexed keywords

EID: 85012503878     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399400001484     Document Type: Article

References (54)

1. Lloyd, K.O. and Furukawa, K. (1998) Biosynthesis and functions of gangliosides: recent advances. Glycoconj J 15, 627–636, PubMed ID:99096096
2. van Echten, G. and Sandhoff, K. (1993) Ganglioside metabolism. Enzymology, Topology, and regulation. J Biol Chem 268, 5341–5344, PubMed ID:93194817
3. Ichikawa, S. and Hirabayashi, Y. (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8, 198–202, PubMed ID:98360952
4. Coetzee, T., Suzuki, K. and Popko, B. (1998) New perspectives on the function of myelin galactolipids. Trends Neurosci 21, 126–130, PubMed ID:98189403
5. Sandhoff, K. and Kolter, T. (1997) Biochemistry of glycosphingolipid degradation. Clin Chim Acta 266, 51–61, PubMed ID:98098319
6. Sandhoff, K. and Kolter, T. (1996) Topology of glycosphingolipid degradation. Trends Cell Biol 6, 98–103
7. Sandhoff, K. and Klein, A. (1994) Intracellular trafficking of glycosphingolipids: role of sphingolipid activator proteins in the topology of endocytosis and lysosomal digestion. FEBS Lett 346, 103–107, PubMed ID:94265904
8. Yamashita, T. et al. (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 96, 9142–9147, PubMed ID:99362724
9. Neufeld, E.F. (1991) Lysosomal storage diseases. Annu Rev Biochem 60, 257–280, PubMed ID:91354029
10. Beutler, E. and Grabowski, G. (1995) Gaucher Disease, McGraw Hill, New York, USA
11. Desnick, R.J., Ioannou, Y.A. and Eng, C. (1995) alpha-galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Diseases (vol. 2) (Scriver, C.R. et al., eds), pp. 2741–2784, McGraw Hill, New York, USA
12. Gravel, R.A. et al. (1995) The GM2 Gangliosidoses. In The Metabolic and Molecular Bases of Inherited Diseases (vol. 2) (Scriver, C.R. et al., eds), pp. 2839–2879, McGraw Hill, New York, USA
13. Barton, N.W. et al. (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 87, 1913–1916, PubMed ID:90175406
14. Cox, T.M. (1994) Therapeutic advances in Gaucher's disease: a model for the treatment of lysosomal storage diseases. Trends Exp Clin Med 4, 144–160
15. Grabowski, G.A. et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122, 33–39, PubMed ID:95077212
16. Erikson, A. et al. (1990) Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand 79, 680–685, PubMed ID:90350517
17. Ringden, O. et al. (1995) Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation 59, 864–870, PubMed ID:95216113
18. Salvetti, A., Heard, J.M. and Danos, O. (1995) Gene therapy of lysosomal storage disorders. Br Med Bull 51, 106–122, PubMed ID:95285147
19. Radin, N.S. (1996) Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 13, 153–157, PubMed ID:96301647
20. Vunnam, R.R. and Radin, N.S. (1980) Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem Phys Lipids 26, 265–278, PubMed ID:80177226
21. Platt, F.M. and Butters, T.D. (1998) New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol 56, 421–430, PubMed ID:98434181
22. Flatz, G. (1995) The genetic polymorphism of intestinal lactase activity in adult humans. In The Metabolic and Molecular Bases of Inherited Diseases (7th edn) (vol. 2) (Scriver, C.R. et al., eds), pp. 4441–4450, McGraw Hill, New York, USA
23. Abe, A. et al. (1992) Improved inhibitors of glucosylceramide synthase. J Biochem (Tokyo) 111, 191–196, PubMed ID:92234982
24. Inokuchi, J. and Radin, N.S. (1987) Preparation of the active isomer of 1-phenyl-2-decanoylamino-3- morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res 28, 565–571, PubMed ID:87252806
25. Platt, F.M. and Butters, T.D. (1995) Inhibitors of glycosphingolipid biosynthesis. Trends Glycosci Glycotechnol 7, 495–511
26. Platt, F.M. et al. (1994) N-butyldeoxy-galactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 269, 27108–27114, PubMed ID:95014583
27. Tan, A. et al. (1991) Chemical modification of the glucosidase inhibitor 1-deoxynojirimycin. Structure-activity relationships. J Biol Chem 266, 14504–14510, PubMed ID:91317812
28. van den Broek, L.A.G.M. et al. (1993) Chemical modification of azasugars, inhibitors of N-glycoprotein-processing glycosidases and of HIV-1 infection. Recl Trav Chim Pays-Bas 112, 82–94
29. Schweden, J. et al. (1986) Characterization of calf liver glucosidase I and its inhibition by basic sugar analogs. Arch Biochem Biophys 248, 335–340, PubMed ID:86267773
30. van den Broek, L.A.G.M. et al. (1994) Synthesis of oxygen-substituted N-alkyl 1-deoxynojirimycin derivatives: aza sugar alpha-glucosidase inhibitors showing antiviral (HIV-1) and immunosuppressive activity. Recl Trav Chim Pays-Bas 113, 507–516
31. Butters, T.D. et al. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tet Asym (in press)
32. Petrescu, A.J. et al. (1997) The solution NMR structure of glucosylated N-glycans involved in the early stages of glycoprotein biosynthesis and folding. Embo J 16, 4302–4310, PubMed ID:97392460
33. Asano, N. et al. (1998) Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem 41, 2565–2571, PubMed ID:98315172
34. Qiao, L. et al. (1996) Synergistic inhibition of human alpha-1,3-fucosyltransferase V. J Am Chem Soc 118, 7653–7662
35. Lee, L., Abe, A. and Shayman, J.A. (1999) Improved inhibitors of glucosylceramide synthase. J Biol Chem 274, 14662–14669, PubMed ID:99262613
36. Platt, F.M. et al. (1997) Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 272, 19365–19372, PubMed ID:97382265
37. Suzuki, K. and Proia, R.L. (1998) Mouse models of human lysosomal diseases. Brain Pathol 8, 195–215, PubMed ID:98117380
38. Suzuki, K. and Mansson, J.E. (1998) Animal models of lysosomal disease: an overview. J Inherit Metab Dis 21, 540–547, PubMed ID:98397580
39. Liu, Y. et al. (1998) Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci U S A 95, 2503–2508, PubMed ID:98151542
40. Yamanaka, S. et al. (1994) Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci U S A 91, 9975–9979, PubMed ID:95024084
41. Taniike, M. et al. (1995) Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol 89, 296–304, PubMed ID:95335135
42. Sango, K. et al. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11, 170–176, PubMed ID:96024653
43. Platt, F.M. et al. (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428–431, PubMed ID:97258948
44. Jeyakumar, M. et al. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 96, 6388–6393, PubMed ID:99272703
45. Liu, Y. et al. (1999) A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J Clin Invest 103, 497–505, PubMed ID:99146964
46. Norflus, F. et al. (1998) Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest 101, 1881–1888, PubMed ID:98244997
47. Fischer, P.B. et al. (1996) N-butyl-deoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J Virol 70, 7143–7152, PubMed ID:96386611
48. Fischer, P.B. et al. (1996) N-butyl-deoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J Virol 70, 7153–7160, PubMed ID:96386612
49. Fischl, M.A. et al. (1994) The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200–500 CD4 cells/mm3. J Acquir Immune Defic Syndr 7, 139–147, PubMed ID:94133083
50. Andersson, U. et al. (2000) N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59, 821–829, PubMed ID: 20181268
51. Phaneuf, D. et al. (1996) Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 5, 1–14, PubMed ID: 96381421
52. Ohshima, T. et al. (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 94, 2540–2544, PubMed ID: 97225989
53. Hahn, C.N. et al. (1997) Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet 6, 205–211, PubMed ID: 97217779
54. Tybulewicz, V.L. et al. (1992) Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357, 407–410, PubMed ID: 92278431